D. E. Shaw & Co., Inc. Beam Therapeutics Inc. Transaction History

D. E. Shaw & Co., Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$21.22 - $32.66 $185,059 - $284,827	8,721 New	8,721 $204,000
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $1.75 Million - $3.09 Million	43,995 New	43,995 $2.1 Million
Q1 2022 May 16, 2022	SELL	$53.73 - $82.16 $927,863 - $1.42 Million	-17,269 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$68.02 - $99.06 $2.86 Million - $4.16 Million	-41,974 Reduced 70.85%	17,269 $1.38 Million
Q3 2021 Nov 15, 2021	BUY	$84.37 - $133.6 $4.48 Million - $7.09 Million	53,047 Added 856.15%	59,243 $5.16 Million
Q1 2021 May 17, 2021	BUY	$71.28 - $120.75 $441,650 - $748,167	6,196 New	6,196 $496,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.